Literature DB >> 8971289

Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans.

B Coffin1, D Bouhassira, R Chollet, B Fraitag, C De Meynard, J Geneve, M Lemann, J C Willer, R Jian.   

Abstract

BACKGROUND AND AIM: Gastric hypersensitivity to mechanical distension has been observed in functional dyspepsia, but no drug is available that specifically acts on gastric afferent pathways to decrease gastric nociception. The aim of this study was to assess the effect of fedotozine, a synthetic ligand for peripheral kappa receptors, on human gastric sensitivity.
METHODS: Twenty-seven healthy volunteers were randomized to receive either fedotozine (30 mg t.d.s.) or a placebo, for 7 days. On day 7, the effects of fedotozine were tested on discomfort threshold and gastric compliance during graded isobaric and isovolumic distensions. In 16 of these subjects, the effect of this drug was tested on somatic sensitivity. In 10 other healthy volunteers the effect of fedotozine on gastric distension-induced inhibition of the RIII reflex, a process closely related to visceral sensitivity, was also studied.
RESULTS: During isobaric distensions, the discomfort threshold was significantly higher in subjects on fedotozine than in those on placebo (14.4 +/- 0.92 vs. 12.0 +/- 1.13 mmHg; P = 0.04). Compared to placebo, fedotozine did not modify gastric compliance and somatic sensitivity. Fedotozine also reduced the inhibition of the RIII reflex induced by gastric distension.
CONCLUSION: Fedotozine decreases gastric sensitivity to distension by exerting specific action on gastric afferent pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971289     DOI: 10.1046/j.1365-2036.1996.109280000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

Review 1.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 2.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Frontiers in functional dyspepsia.

Authors:  Noel R Fajardo; Filippo Cremonini; Nicholas J Talley
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 4.  Causes and treatment of functional dyspepsia.

Authors:  J Tack; R Bisschops; B DeMarchi
Journal:  Curr Gastroenterol Rep       Date:  2001-12

5.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

6.  Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation.

Authors:  J-M Sabaté; D Bouhassira; C Poupardin; A Wagner; Y Loria; B Coffin
Journal:  Neurogastroenterol Motil       Date:  2007-11-14       Impact factor: 3.598

Review 7.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

8.  Current treatments in functional dyspepsia.

Authors:  Meredythe A McNally; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04

9.  Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.

Authors:  N J Talley; R S Choung; M Camilleri; R A Dierkhising; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2008-03-07       Impact factor: 8.171

10.  Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome.

Authors:  B Coffin; D Bouhassira; J-M Sabaté; L Barbe; R Jian
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.